Latest Headlines

Latest Headlines

Sangart goes MIA after burning through $260M-plus on R&D

San Diego-based Sangart has gone missing in action after apparently burning through more than a quarter-billion dollars of Leucadia National cash.

UPDATED: Sangart stashes $50M funding for oxygenation drugs

The seventh-round financing is expected to fuel development of San Diego-based Sangart's treatments that deliver essential gases to embattled tissues.

Sangart raises $50M to fund critical Ph2b ischemia study

Investors have anted up $50 million to back Sangart's ambitious effort to develop a molecule that can carry badly needed oxygen to various tissue targets in the body. Leucadia National Corporation

Sangart garners $50M in new Series F cash

San Diego-based Sangart has raised $50 million from its Series F. The money comes from the exercise of warrants issued in 2007 and it brings the total amount of cash raised in the investment round to

Sangart axes staff, focuses on lead therapy

San Diego-based Sangart is restructuring, triggering a "significant reduction in work force" as it names four new additions to its executive staff. The executive changes include the appointment of